University of New Mexico

UNM Digital Repository
Pediatrics Research and Scholarship

Pediatrics

6-1-2021

Effect of blood transfusions on cognitive development in very low
birth weight infants
Priya Shah
Daniel C Cannon
Jean R Lowe
John Phillips
Robert D Christensen

See next page for additional authors

Follow this and additional works at: https://digitalrepository.unm.edu/peds_pubs

Authors
Priya Shah, Daniel C Cannon, Jean R Lowe, John Phillips, Robert D Christensen, Beena Kamath-Rayne,
Adam Rosenberg, Susan Wiedmeier, Shrena Patel, Sarah Winter, Shawna Baker, and Robin K Ohls

HHS Public Access
Author manuscript
Author Manuscript

J Perinatol. Author manuscript; available in PMC 2021 October 28.
Published in final edited form as:
J Perinatol. 2021 June ; 41(6): 1412–1418. doi:10.1038/s41372-021-00997-9.

Effect of Blood Transfusions on Cognitive Development in Very
Low Birth Weight Infants
Priya Shah, MD1, Daniel C Cannon, MS2, Jean R Lowe, PhD3, John Phillips, MD4, Robert D
Christensen, MD5, Beena Kamath-Rayne, MD6, Adam Rosenberg, MD7, Susan Wiedmeier,
MD5, Shrena Patel, MD8, Sarah Winter, MD5, Shawna Baker, RN9, Robin K Ohls, MD5
1Presbyterian

Author Manuscript

2Iterative

Consulting, Albuquerque, New Mexico

3Department
4Mind

Medical Group, Pediatrics, Albuquerque, New Mexico

of Pediatrics, University of New Mexico, Albuquerque, New Mexico

Research Network, Albuquerque, New Mexico

5Department

of Pediatrics, University of Utah, Salt Lake City, Utah

6American

Academy of Pediatrics, Itasca, Illinois

7University

of Colorado, Aurora, Colorado

8MEDNAX,

Seattle, Washington

9CCTS,

University of Utah, Salt Lake City, Utah

Author Manuscript

Abstract
Objective: Preterm infants frequently receive red cell transfusions; however, the effect of
transfusions on cognition is unclear. We evaluated the relationship between transfusions and
cognitive outcomes in preterm infants enrolled in a randomized trial of erythropoiesis stimulating
agents (ESAs).
Study Design: Preterm infants were randomized to ESAs or placebo during initial
hospitalization, and transfusions recorded. Children were evaluated using standard developmental
tests of cognition at 18–22 months (56 ESA, 24 placebo) and 3.5–4 years (39 ESA, 14 placebo)
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Results: Cognitive scores at 18–22 months were inversely correlated with transfusion volume at
(p=0.02). Among those receiving ≥1 transfusion, cognitive scores were significantly higher in the
ESA-treated group (p=0.003). At 3.5–4 years, transfusions weren’t correlated with cognitive
scores.
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Conclusions: In the placebo group, transfused children had lower cognitive scores than did nontransfused children at 18–22 months. In the ESA group, cognitive scores did not differ by
transfusion status, suggesting ESAs provide neuroprotection.
Keywords
prematurity; erythropoietin; darbepoetin; neuroprotection

Introduction
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Preterm infants who receive red blood cell (RBC) transfusions are more likely than matched
un-transfused controls to experience common morbidities such as bronchopulmonary
dysplasia [1, 2], sepsis [1], retinopathy of prematurity [3], necrotizing enterocolitis (NEC)
[3,4], and intraventricular hemorrhage (IVH) [4–6]. While a cause-and-effect has not been
established, the association between transfusions and common morbidities have prompted
clinicians to re-evaluate the safety and value of RBC transfusion guidelines.
Few studies have focused on the roles transfusions and recombinant erythropoietin (Epo)
play on neuronal development. It is unknown whether better cognitive outcomes are a result
of neuroprotective effects of erythropoiesis stimulating agents (ESAs), improved
oxygenation due to higher hematocrit in ESA recipients, increased neuronal injury or
morbidity due to transfusions, a combination of these, or other factors – associations we feel
deserve further study.
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ESAs such as Epo and Darbepoetin alfa (Darbe) increase red cell mass and decrease
transfusion requirements [7]. In our previously reported randomized controlled trial that
incorporated standardized transfusion guidelines, ESA recipients received significantly
fewer transfusions and were exposed to fewer donors [8]. In addition, 58% of ESA
recipients did not receive a transfusion, compared to 38% in the placebo group [8].
Evaluating those infants at 18–22 months, we found that the ESA recipients had better
cognitive outcomes than did the placebo recipients [9]. Developmental testing at 3.5–4 years
of age continued to show better cognitive outcomes of the ESA recipients [10]. These
improvements included better scores in domains of executive function: working memory,
cognitive flexibility, and impulse control.
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However, it is unclear whether the better cognitive outcomes were due to neuroprotective
effects of ESAs, higher hematocrits in ESA recipients (8), fewer transfusion in the ESA
recipients, or some combination of these factors. To more clearly understand our observed
outcomes, we performed a secondary analysis of our ESA trial and correlated the transfusion
number and volume each study infant received with their developmental scores at 18–22
months and 3.5–4 years. We hypothesized that transfusions and transfusion volumes would
be inversely correlated with cognitive outcome.
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Methods
Initial ESA Study:
Subjects: Preterm infants 500–1,250 grams birth weight were enrolled in either ESA or
placebo treatment arms at ≤48 hours after birth. Randomization was stratified by center
(New Mexico, Utah and Colorado) using a computer-generated permuted block method. All
care givers and investigators (except the research pharmacists and coordinators
administering the study medicine) were masked to the treatment assignment. An
investigational new drug application was approved by the Federal Drug Administration (IND
#100138), and the study was registered on ClinicalTrials.gov (NCT00334737).
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Dosing of Study Drug and supplements: Infants were randomized to one of three
groups: Epo, 400 units/kg, given subcutaneously (SC) three times a week; Darbe, 10 μg/kg,
given SC once a week, with sham dosing two other times per week; or placebo, consisting of
three sham doses per week. Dosing continued until 35 completed weeks gestation,
discharge, transfer to another hospital, or death. All infants received supplemental iron,
folate, and vitamin E.
Transfusion Guidelines: A standardized uniform transfusion protocol, based on
hematocrit/hemoglobin levels and respiratory support, was used to determine when infants
would be transfused (Table 1).
Developmental Follow-Up at 18–22 months
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Children were evaluated at 18–22 months corrected age at the New Mexico, Utah, and
Colorado sites by examiners blinded to the treatment group. The study was approved by the
IRBs at the Universities of New Mexico, Utah, and Colorado, and informed consent was
obtained from parents. Cognitive outcomes were assessed using the Bayley Scales of Infant
Development III (BSID). Composite cognitive, language, social/emotional, and object
permanence scores (a subset of the BSID evaluating executive function) were determined.
Developmental Follow up at 3.5–4 years
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Children previously enrolled in this study were eligible for the BRITE Study (BRain
Imaging and Developmental Follow-up of Infants Treated with Erythropoietin;
NCT01207778), performed at the Utah and New Mexico sites. Because a new informed
consent was required for the BRITE study, not all previous subjects were enrolled; therefore,
sample size estimates were not performed. Children were evaluated at 3.5–4 years of age at
the New Mexico or Utah sites by examiners who remained blinded to the treatment group.
Cognitive outcomes were assessed using the Wechsler Preschool and Primary Scale of
Intelligence III (WPPSI). The WPPSI test involved the administration of verbal,
performance, and general language scales to calculate a Full-Scale IQ score (combination of
verbal and performance scales).
Statistical Analysis
Baseline characteristics, growth, and medical outcomes were compared between ESA and
placebo treatment arms using Kruskal-Wallis tests for quantitative dependent variables and
J Perinatol. Author manuscript; available in PMC 2021 October 28.
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chi-squared tests for nominal and categorical dependent variables. A linear regression model
(ESA and placebo recipients combined) was used to compare cognitive scores from BSID
and WPPSI-III with transfusion number or volumes recorded during the initial hospital stay.
We performed initial analyses to determine if there should be a sex interaction term in our
model. We found that sex as an interaction term was not significant and was therefore not
included. Subjects were grouped according to transfusion status: infants who received no
transfusions were compared to infants who received ≥ 1 transfusion.

Results

Author Manuscript

A total of 99 infants participated in the original randomized control trial, 33 per treatment
arm (Darbe, Epo, and placebo; Figure 1 online). Ninety-two infants survived to discharge.
At 18–22 months of age, 80 infants were evaluated (24 placebo, 56 ESA treated). Fourteen
infants were lost to follow up due to reasons including parent refusal (39%), consent not
requested (5%), or enrollment in other studies (37%) [8]. At 3.5–4 years, 39 ESA-treated
children and 14 placebo-treated children were evaluated. Analysis of data between those
who received Epo and those who received Darbe revealed no differences in cognitive testing
or transfusion exposure, thus their data were compiled into one ESA group.
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Characteristics of study subjects at initial enrollment, at 18–22 months, and at 3.5–4 years
are shown in Table 2. There were no differences in birth weight, gestational age, and gender
between ESA and placebo groups. As published previously, infants in the placebo group
received significantly more transfusions (p=0.04) and greater transfusion volumes (p=0.03)
compared to infants in the ESA-treated group [8]. Twelve of 33 of the placebo recipients
(36%) did not receive a transfusion during hospitalization, while 37 of 66 (56%) of ESA
recipients did not receive transfusions. No infant received a transfusion following discharge
from the hospital. Characteristics of study subjects at the follow up periods, shown in Table
2, revealed that the age at follow up did not differ between treatment groups. Children in the
placebo group were more likely to have neurodevelopmental impairment compared to ESAtreated infants (p = 0.005 at 18–22 months and 0.007 at 3.5–4 years) [8–10].
Of those infants seen at 18–22 months, a similar percentage (compared to their hospital
phase) of non-transfused infants were seen: 10 of 24 (42%) placebo recipients (compared to
36% during hospitalization) and 33 of 56 [59%] ESA recipients (compared to 56% during
hospitalization). A similar percentage (compared to hospital phase and 18–22 month follow
up) of non-transfused subjects were seen in each group at 3.5–4 years as well (29% placebo,
59% ESA).
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At 18–22 months, red cell transfusion volumes were inversely correlated with composite
cognitive scores (r= −0.26, p=0.02, Figure 2A). There was a trend toward an inverse
relationship between transfusion number and cognitive scores, which did not reach statistical
significance (Figure 2B, r= −0.37; p=0.077). Transfusion volumes were also inversely
correlated with social/emotional scores (p=0.05; data not shown) but not language scores
(p=0.22; data not shown).
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Among those who received one or more transfusions, both cognitive (p=0.003) and language
(p=0.03) scores were significantly higher in the ESA-treated group than the placebo group
(Figure 3A and B). There were no differences in cognitive (p=0.76) or language (p=0.62)
scores between ESA and placebo groups in those infants who had not received any
transfusions.
At 3.5–4 years, transfusion number (p=0.5) and volume (p=0.61) did not correlate with full
scale IQ (data not shown). Cognitive scores remained similar in the ESA-treated group
whether infants were transfused or not (Figure 4). ESA-treated infants had significantly
higher cognitive scores than placebo-treated infants (Figure 4), in those receiving no
transfusions (p=0.05) and those receiving ≥1 transfusion (p=0.03).

Discussion
Author Manuscript

We evaluated the relationship between number and volume of RBC transfusions and longterm neurocognitive outcomes, among former preterm infants randomized to treatment with
ESAs or placebo. Ours is the first study to report this relationship.
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For all former preterm children in this study, cognitive scores at 18–22 months of age
correlated inversely with red cell volume and number of transfusions received as neonates.
At 4-year follow-up, this relationship was no longer apparent. However, cognitive scores at
18–22 months were significantly lower in the subset of placebo recipients who received any
transfusions compared to those who remained non-transfused. Cognitive scores at 18–22
months and 3.5–4 years were similar between transfused and non-transfused infants in the
ESA-treated group. Cognitive scores in the placebo group decreased at the 3.5–4 year visit,
which may reflect worsening impairment in the placebo group over time that was not
previously identified at 18–22 months. Thus, we speculate that transfusions might negatively
impact cognitive development, and that ESAs provide neuroprotection from these negative
effects.
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In studies of adults by Carson et al, liberal transfusion guidelines called for administering
transfusions when the hemoglobin level fell below 10 g/dL, while restrictive transfusion
guidelines did not call for transfusions unless hemoglobin levels fell below 7–8 g/dL [11].
Liberal transfusion guidelines resulted in a greater number and volume of transfusions in
order to maintain higher hemoglobin concentrations. In other studies of adult patients, the
risk of a major infection post-transfusion increased 29% with each RBC unit transfused [12,
13]. These findings have led researchers and health professionals to discuss when and
exactly how many transfusions are optimal. In adults, a restrictive transfusion strategy
lowers overall hospital mortality rates, including decreasing post-transfusion myocardial
infarction rates [11, 13]. Studies assessing the effect of either liberal or restrictive
transfusion guidelines in adults with acute upper gastrointestinal hemorrhage, as well as
those recovering from cardiac surgery, found that morbidity and mortality rates between
groups were comparable [14, 15]. The results of these studies indicate that more transfusions
may not be as beneficial as previously thought, especially for critically ill adults [16].
Similarly, a meta-analysis assessing RBC transfusions in adults undergoing cardiac surgery
found that those who received transfusions had higher mortality rates than those who did not
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receive any, supporting the idea that a restrictive transfusion strategy may be more beneficial
for patients with stable cardiac disease [13].
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In neonatal patients, anemia has been linked to increased intra-hospital morbidity and
mortality rates. Preoperative anemia, defined as a hematocrit ≤ 40%, was a significant,
independent risk factor for postoperative mortality in neonates undergoing non-cardiac
surgery [17]. A hemoglobin ≤ 8 g/dL was also found to be an independent risk factor for
NEC in very low birth weight infants (VLBW). Though transfusion was not found to be an
independent risk factor for NEC, the same study found the incidence of NEC to be higher in
infants who received RBC transfusions versus those who did not [18]. VLBW infants are at
a higher risk of anemia of prematurity and therefore typically receive more transfusions than
do larger infants. However, intrahospital mortality has been found to be significantly higher
in VLBW receiving transfusions [2, 19]. A meta-analysis assessing transfusions in neonates
suggest that there is no significant difference in morbidity and mortality rates between
restrictive and liberal transfusion strategies [20].
Although preterm infants are maintained at higher hemoglobin levels in order to increase
systemic oxygen transport to tissues, higher hemoglobin levels do not necessarily improve
oxygen uptake [21]. In a retrospective analysis, infants maintained at lower hemoglobin
levels had fewer episodes of tachycardia and apnea associated with anemia of prematurity
[3]. Furthermore, studies evaluating the pathogenesis of IVH suggested that because preterm
infants lack the structural support of the microvasculature in the brain, wide fluctuations in
blood flow might result in rupture and hemorrhage of capillaries resulting in IVH [4–6].
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In a randomized trial by Neubauer et al, neurodevelopmental impairment, defined as
cognitive scores <70, blindness, deafness, or cerebral palsy was greater in the placebo group
[22]. These preterm infants received the greatest number of transfusions [8]. There have
been conflicting reports on the developmental outcomes of infants (not receiving ESAs) who
were randomized to liberal or restrictive transfusion strategies. Kirpalani and colleagues [23]
randomized 451 infants to a low or high threshold hemoglobin strategy and reported no
difference in neurologic morbidities between groups; however, analyses at 2 years of age
revealed increased number of infants with BSID II mental developmental index<80 in the
low hemoglobin threshold group [21]. Conversely, improved cognition and brain growth
were reported in the restrictively transfused group of the Iowa study by Bell and colleagues
[24, 25], underscoring the need for long term evaluation and more comprehensive study.
These investigators are collaborating on an ongoing NICHD Neonatal Research Network
study, the Transfusion of Prematures Trial (TOP; Clinical Trials #NCT01702805). Over
1800 ELBW infants were randomized to a liberal or restrictive transfusion strategy. The
primary outcome of the presence or absence of neurodevelopmental impairment at 2 years
will soon be published. A similarly designed study, the Effects of Transfusion Thresholds on
Neurocognitive Outcome (ETTNO) study, was recently completed [26]. Investigators
showed no significant differences in cognitive outcomes among ELBW infants randomized
to liberal or restrictive transfusion strategies. They concluded that a liberal blood transfusion
strategy did not reduce the likelihood of death or disability at 24 months compared with a
restrictive strategy.
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The non-hematopoietic benefits of ESAs have been studied in clinical trials and animal
models. A recent randomized control trial found that the early administration of high-dose
Epo is safe in premature infants. Infants given Epo experienced no increase in mortality or
morbidity, such as arterial hypertension, polycythemia, or thromboembolic events, and had
significantly higher hematocrit levels compared to the placebo group [27]. Previous research
in animal models found Epo receptors on astrocytes, neurons, and oligodendrocytes. Epo has
been described as a neurotrophic agent, as it increases neurogenesis and oligodendrogenesis,
allowing for growth of the developing brain [28–30]. Moreover, Epo has neuroprotectant and
neuroreparative effects, and has anti-inflammatory actions in the central nervous system,
reducing pro-inflammatory cytokine effects and thereby minimizing neuronal injury [28–
30]. In contrast, RBC transfusions of preterm neonates are associated with an increase in
blood concentrations of pro-inflammatory cytokines [31]. Recent clinical studies report that
Epo treatment within 42 hours of birth is associated with decreased incidence of
encephalopathy of prematurity, as indicated by a decrease in periventricular white matter
loss and gray matter injury [29]. Epo-treated neonates also show improved white matter
development that may be associated with neuronal healing [30].
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The hypothesis-generating observations reported here focus on the roles transfusions and
Epo play on neuronal development. It is unknown whether better cognitive outcomes are a
result of neuroprotective effects of ESAs, improved oxygenation due to higher hematocrit in
ESA recipients, increased neuronal injury or morbidity due to transfusions, a combination of
these, or other factors – a correlation that requires further study. A major limitation of this
study is that our sample size was small, although we were able to follow subjects
longitudinally over a four year period. The results from the TOP trial and the ETTNO study
will provide outcome data on over 2,700 extremely low birth weight infants. Based on our
work, we speculate that there will be no difference in developmental outcomes between
infants transfused at a higher hematocrit threshold compared to those transfused at a lower
hematocrit threshold. In addition, the Epo for neuroprotection trial (PENUT;
#NCT01534481) and a Neonatal Research Network trial of Darbepoetin administration to
preterm infants (#NCT03169881) will provide transfusion data on over 3000 extremely low
gestational age infants randomized to an ESA or placebo. Evaluating the relationship
between cognitive outcomes at 2 years and transfusion number and volume (with or without
the addition of ESAs) will provide significant insight into the role red cell transfusions play
in the developmental outcomes of infants born prematurely.
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Darbe

darbepoetin alfa

ELBW

extremely low birth weight

Epo

erythropoietin

ESA

erythropoiesis stimulating agents

VLBW

very low birth weight

BSID-III

Bayley Scale of Infant Development III

WPPSI-III

Wechsler Preschool and Primary Scale of Intelligence III

OP

object permanence

CP

cerebral palsy

FSIQ

Full Scale IQ

PIQ

Performance IQ

VIQ

Verbal IQ
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Figure 1:

Numbers of infants who were screened for eligibility, randomly assigned to receive Epo,
Darbe, or placebo, and followed 18–22 months and 3.5–4 years of age.
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Figure 2:

Relationship between BSID-III composite cognitive scores and transfusions. (A) cognitive
scores versus transfusion volume (p=0.02); (B) cognitive scores versus transfusion number
(p=0.077). There was a significant inverse relationship between cognitive scores and
transfusion volume.
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Figure 3:
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Comparison of BSID-III (A) composite cognitive scores and (B) language scores at the 18–
22 month follow up period between ESA-treated and placebo-treated infants; grouped by
receiving either no transfusions or ≥1 transfusion. In infants receiving ≥1 transfusion, ESAtreated infants had significantly higher composite cognitive scores (0= 0.003) and language
scores (p=0.03) when compared to placebo-treated infants.
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Figure 4:

Comparison of WPPSI-III Full Scale IQ (FSIQ) scores at the 3.5–4 year follow up period
between ESA-treated and placebo-treated infants; grouped by receiving either no
transfusions or ≥1 transfusion. By 3.5–4 years of age, there were no differences in cognition
in the placebo group between those who, as infants, received transfusions and those who did
not.
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Transfusion protocol
Hematocrit/
hemoglobin

Transfusion
Volume

Respiratory support and/or symptoms

30 %/10 grams/dL

15 mL/kg

moderate/significant ventilation (MAP >8 cm H2O AND FiO2 >0.4)

25%/8 grams/dL

20 mL/kg

minimal respiratory support (any mechanical ventilation with FiO2 ≤0.4, OR CPAP >6 cm
H2O and FiO2 ≥0.4)

20%/7 grams/dL

20 mL/kg

supplemental oxygen OR CPAP with an FiO2≤0.4, AND at least one of the following:
• ≥24 hours of tachycardia (heart rate >180) or tachypnea (RR >60);
• a doubling of the oxygen requirement from the previous 48 hours
• lactate ≥2.5 mEq/L or an acute metabolic acidosis (pH<7.20);
• weight gain <10 grams/kg/day over the previous 4 days while receiving ≥120 kcal/kg/
day;
• undergoing surgery within 24 hours

18%/6 grams/dL

20 mL/kg

Asymptomatic AND an absolute reticulocyte count <100,000 cells/μL
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Summarized from reference 8.
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Subject Characteristics
Initial Enrollment

Placebo

ESA

p

Subjects — no.

33

66

Female — no. (%)

9 (38)

27 (48)

1.0

Birth weight (g) — median (IQR)

1005.0 (220.5)

946.0 (351.0)

0.9

Gestation (weeks) — median (IQR)

28.0 (1.2)

28.0 (2.0)

0.51

Transfusion Number — median (IQR)

3 (4)

1 (2)

0.04

Transfusion Volume — median (IQR)

53 (58)

21(32)

0.03

ROP, Stage ≥ 3 requiring intervention— no. (%)

1 (4.2)

2 (3.6)

NS

IVH, Stage ≥ 3 — no. (%)

5 (20.8)

4 (7.1)

NS

NEC — no. (%)

1 (4.2)

1 (1.8)

NS

BPD — no. (%)

14 (58.3)

37 (66)

NS

18–22 Months Follow Up

Placebo

ESA

p

24

56

20 (1)

21 (2)

NS

Composite Cognitive Score— mean (s.d.)

88.7 (13.5)

96.5 (11.2)

0.01

Composite Language Score — mean (s.d.)

83.6 (13.1)

90.7 (15.4)

0.05

Object Permanence — mean (s.d.)

2.2 (1.0)

2.6 (0.7)

0.05

10 (41.7)

7 (12.5)

0.005

Cognitive score < 70 — no. (%)

2 (8.3)

1 (1.8)

0.2

Cerebral Palsy — no. (%)

5 (20.8)

0 (0)

0.002

Hearing Impairment — no. (%)

1 (4.2)

1 (1.8)

NS

Visual Impairment — no. (%)

1 (4.2)

2 (3.6)

NS

3.5–4 Year Follow Up

Placebo

ESA

p

Subjects — no.

14

39

Age at follow up (mos.) — median (IQR)

48 (3)

49 (40)

NS

Full-scale IQ— mean (s.d.)

78.9 (18.9)

91.1 (17.5)

0.036

Performance IQ— mean (s.d.)

79.5 (19.5)

93.0 (17.0)

0.018

Verbal IQ— mean (s.d.)

82.9 (16.9)

91.7 (18.3)

0.091

Hospital Morbidities:
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Subjects — no.
Age at follow up (mos.) — median (IQR)
Developmental assessments:

Neurodevelopmental Impairment:
Any NDI — no. (%)

Author Manuscript

Developmental assessments:

Neurodevelopmental Impairment:
Any NDI — no. (%)

Author Manuscript

6 (43)

3 (8)

0.007

Full-scale IQ < 70 — no. (%)

4 (29)

3 (8)

0.070

Cerebral Palsy — no. (%)

3 (21)

0 (0)

0.016

Hearing Impairment — no. (%)

0 (0)

0 (0)

NS

Visual Impairment — no. (%)

0 (0)

0 (0)

NS

Data are reported as median (first-third interquartile range), or percent. Data compiled from references [8] and [9]. ROP: Retinopathy of
prematurity; IVH: Intraventricular hemorrhage; NEC: necrotizing enterocolitis; BPD: bronchopulomonary dysplasia; NDI: neurodevelopmental
impairment
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